Up-regulation of kin17 is essential for proliferation of breast cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Zeng, Tao ^a   Gao, Hongyi ^b   Yu, Pei ^a   He, Heng ^a   Ouyang, Xiaoming ^c   Deng, Lijuan ^a   Zhang, Yan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Women and Children's Hospital and Health Institute   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; DNA BINDING PROTEIN; KIN PROTEIN, HUMAN; RNA BINDING PROTEIN;

ADULT; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STIMULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; GENE CONTROL; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIN17 GENE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; BREAST TUMOR; CELL CYCLE; DISEASE COURSE; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADULT; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA REPAIR; DNA REPLICATION; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; RNA-BINDING PROTEINS; UP-REGULATION;

EID: 80053327867     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025343     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, et al. (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69: 4951-4953.
3. Kannouche P, Mauffrey P, Pinon-Lataillade G, Mattei MG, Sarasin A, et al. (2000) Molecular cloning and characterization of the human KIN17 cDNA encoding a component of the UVC response that is conserved among metazoans. Carcinogenesis 21: 1701-1710.
4. le Maire A, Schiltz M, Stura EA, Pinon-Lataillade G, Couprie J, et al. (2006) A tandem of SH3-like domains participates in RNA binding in KIN17, a human protein activated in response to genotoxics. J Mol Biol 364: 764-776.
5. Mazin A, Milot E, Devoret R, Chartrand P, (1994) KIN17, a mouse nuclear protein, binds to bent DNA fragments that are found at illegitimate recombination junctions in mammalian cells. Mol Gen Genet 244: 435-438.
6. Miccoli L, Frouin I, Novac O, Di Paola D, Harper F, et al. (2005) The human stress-activated protein kin17 belongs to the multiprotein DNA replication complex and associates in vivo with mammalian replication origins. Mol Cell Biol 25: 3814-3830.
7. Pinon-Lataillade G, Masson C, Bernardino-Sgherri J, Henriot V, Mauffrey P, et al. (2004) KIN17 encodes an RNA-binding protein and is expressed during mouse spermatogenesis. J Cell Sci 117: 3691-3702.
8. Masson C, Menaa F, Pinon-Lataillade G, Frobert Y, Chevillard S, et al. (2003) Global genome repair is required to activate KIN17, a UVC-responsive gene involved in DNA replication. Proc Natl Acad Sci U S A 100: 616-621.
9. Biard DS, Saintigny Y, Maratrat M, Paris F, Martin M, et al. (1997) Enhanced expression of the Kin17 protein immediately after low doses of ionizing radiation. Radiat Res 147: 442-450.
10. Biard DS, Miccoli L, Despras E, Frobert Y, Creminon C, et al. (2002) Ionizing radiation triggers chromatin-bound kin17 complex formation in human cells. J Biol Chem 277: 19156-19165.
11. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA, (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193-204.
12. Bartek J, Bartkova J, Lukas J, (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26: 7773-7779.
13. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
14. de Azambuja E, Cardoso F, de Castro GJ, Colozza M, Mano MS, et al. (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504-1513.
15. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
16. Reddy TK, Seshadri P, Reddy KK, Jagetia GC, Reddy CD, (2008) Effect of Terminalia arjuna extract on adriamycin-induced DNA damage. Phytother Res 22: 1188-1194.
17. Salti GI, Das GT, Constantinou AI, (2000) A novel use for the comet assay: detection of topoisomerase II inhibitors. Anticancer Res 20: 3189-3193.
18. Collins AR, (2004) The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 26: 249-261.
19. Zhijian C, Xiaoxue L, Yezhen L, Shijie C, Lifen J, et al. (2010) Impact of 1.8-GHz radiofrequency radiation (RFR) on DNA damage and repair induced by doxorubicin in human B-cell lymphoblastoid cells. Mutat Res 695: 16-21.
20. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW, (1999) Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism. Cancer Res 59: 5475-5478.
21. Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, et al. (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 10: 902-911.
22. Miccoli L, Biard DS, Creminon C, Angulo JF, (2002) Human kin17 protein directly interacts with the simian virus 40 large T antigen and inhibits DNA replication. Cancer Res 62: 5425-5435.
23. Kannouche P, Pinon-Lataillade G, Tissier A, Chevalier-Lagente O, Sarasin A, et al. (1998) The nuclear concentration of kin17, a mouse protein that binds to curved DNA, increases during cell proliferation and after UV irradiation. Carcinogenesis 19: 781-789.
24. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323.
25. Ewen ME, Lamb J, (2004) The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10: 158-162.
26. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, et al. (2006) Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 66: 11389-11398.
27. Maslon MM, Hupp TR, (2010) Drug discovery and mutant p53. Trends Cell Biol 20: 542-555.
28. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, et al. (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9: R30.
29. Hussain SA, Palmer DH, Spooner D, Rea DW, (2007) Molecularly targeted therapeutics for breast cancer. BioDrugs 21: 215-224.
30. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312.
31. Boccardo F, Rubagotti A, (2007) Switching to aromatase inhibitors in early breast cancer. Lancet 369: 533-535.
32. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36.
33. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, et al. (2009) Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4: e5565.
34. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A, (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36: 206-215.
35. Carey L, Winer E, Viale G, Cameron D, Gianni L, (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692.
36. Milanezi F, Carvalho S, Schmitt FC, (2008) EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 8: 417-434.
37. Lacroix M, Leclercq G, (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289.
38. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641-2650.
39. Venkatesha VA, Kalen AL, Sarsour EH, Goswami PC, (2010) PCB-153 exposure coordinates cell cycle progression and cellular metabolism in human mammary epithelial cells. Toxicol Lett 196: 110-116.